[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Rhythm Pharmaceuticals, Inc.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":79},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,47],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":32,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100574535","phase-3-a-trial-of-setmelanotide-in-patients-with-congenital-hypothalamic-obesity-sub-study-of-nct05774756-100574535",false,"NCT06760546","A Trial of Setmelanotide in Patients With Congenital Hypothalamic Obesity (Sub-study of NCT05774756)","A Phase 3, Double Blind, Randomized, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Setmelanotide in Patients With Acquired Hypothalamic Obesity","Key Inclusion Criteria:\n\n1. Diagnosis of multiple pituitary hormone deficiency (MPHD), or septo-optic dysplasia (SOD), or optic nerve hypoplasia (ONH), or Childhood-onset combined pituitary hormone deficiency (CPHD), or Pituitary Stalk Interruption Syndrome (PSIS) with at least one pituitary deficiency AND a body mass index (BMI) of ≥30 kg\u002Fm2 for patients ≥18 years of age, or BMI ≥95th percentile for age and sex for patients 4 to \\\u003C18 years\n2. Age 4 years and older\n3. Weight gain associated with the hypothalamic injury and a BMI of ≥30 kg\u002Fm2 for patients ≥18 years of age or BMI ≥95th percentile for age and sex for patients 4 to \\\u003C18 years of age\n4. Agree to use a highly effective form of contraception throughout the study and for 90 days after the study\n\nKey Exclusion Criteria:\n\n1. Diagnosis of Prader-Willi syndrome (PWS) or Rapid-onset obesity with hypoventilation, hypothalamic, autonomic dysregulation, neuroendocrine tumor syndrome (ROHHADNET)\n2. Weight loss \\>2% in the previous 3 months for patients aged ≥18 years or \\>2% reduction in BMI for patients aged 4 to \\\u003C18 years\n3. Bariatric surgery or procedure within last 2 years\n4. Diagnosis of severe psychiatric disorders; any suicidal ideation, attempt or behavior\n5. Current, clinically significant pulmonary, cardiac, metabolic, or oncologic disease\n6. Significant dermatologic findings relating to melanoma or pre-melanoma skin lesions (excluding non-invasive basal or squamous cell lesion)\n7. History or close family history of skin cancer or melanoma\n8. Participation in any clinical trial with an investigational drug\u002Fdevice within 3 months prior to the first trial dose\n9. Previously enrolled in a clinical trial involving setmelanotide or any previous exposure to setmelanotide\n10. Inability to comply with once daily (QD) injection regimen\n11. If female, pregnant and\u002For breastfeeding.\n12. If receiving hormone replacement therapy, dose has remained stable for at least 2 months before Screening\n\nOther protocol defined Inclusion\u002FExclusion criteria may apply.","ALL","4 Years",{"count":19,"type":20},39,"ESTIMATED","INTERVENTIONAL",[23],"PHASE3","This is a sub-study of Study RM-493-040 (NCT05774756).\n\nThe goal of this sub-study is to learn how well Setmelanotide works to improve weight reduction, hunger, and quality of life in patients 4 years of age and older with congenital Hypothalamic Obesity (cHO). To determine how well setmelanotide works and how safe it is, patients with cHO will take a daily injection of either setmelanotide or placebo and complete trial assessments for up to 26 weeks on a therapeutic regimen.",[26,27,28,29,30,31],"Hypothalamic Obesity","Multiple Pituitary Hormone Deficiency Genetic Form","Septo-Optic Dysplasia","Optic Nerve Hypoplasia","Childhood-onset Combined Pituitary Hormone Deficiency","Pituitary Stalk Interruption Syndrome",[33],"melancortin 4 receptor, MC4R","RECRUITING","2026-02-10",{"date":37,"type":38},"2026-02-12","ACTUAL",{"date":40,"type":38},"2025-09-23",{"date":42,"type":20},"2028-03-13",{"name":44,"class":45},"Rhythm Pharmaceuticals, Inc.","INDUSTRY",11,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":54,"sex":16,"minAge":55,"maxAge":56,"enrollmentInfo":57,"targetDuration":4,"studyType":21,"phases":59,"briefSummary":62,"conditions":63,"keywords":66,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":78},"100534460","phase-1-a-study-of-rm-718-in-healthy-subjects-and-patients-with-mc4r-pathway-impairment-100534460","NCT06239116","A Study of RM-718 in Healthy Subjects and Patients With MC4R Pathway Impairment","A Study of RM-718 Weekly Formulation in Healthy Subjects With Obesity and in Patients With Obesity Due to MC4R Impairment","Key Inclusion Criteria:\n\nParts A and B:\n\n* Male and female subjects in good health aged 18-55 years of age at Screening.\n* Body mass index (BMI) ≥30 kg\u002Fm2.\n* Subjects who are medically healthy with normal or clinically insignificant screening results.\n* Subjects must use a highly effective form of contraception and follow the study contraception requirements.\n* Ability to communicate well with the Investigator, understand and comply with the requirements of the trial, and understand English and sign the written informed consent.\n\nPart C:\n\n* Male and female patients with HO, aged 12-65 years of age at Screening.\n* Patient has documented evidence of acquired HO defined as:\n\n  * Diagnosis of craniopharyngioma or other brain lesion affecting the hypothalamic region and has undergone surgery, or chemotherapy, or radiation therapy involving the hypothalamus at least 6 months before Screening, OR\n  * Documented injury to the hypothalamus at least 6 months before Screening for which surgery\u002Fradiation is not indicated.\n* Weight gain associated with the hypothalamic injury either before or following therapy (surgery and\u002For following chemotherapy or radiotherapy), and a BMI of ≥30 kg\u002Fm2 for patients ≥18 years of age or BMI ≥95th percentile for age and sex for patients 12 to \\\u003C18 years of age.\n* Patients must use a highly effective form of contraception and follow the study contraception requirements.\n* Ability to communicate with the Investigator, understand and comply with the requirements of the trial, and understand and sign the written informed consent and assent (for patients aged \\\u003C18 years), and informed consent for a parent or guardian of any patient \\\u003C18.\n\nPart D:\n\n* Confirmed diagnosis of PWS as determined by the Investigator at the time of Screening.\n* Age ≥12 to 65, inclusive, at the time of signing Informed Consent and\u002For Assent.\n* BMI ≥30 kg\u002Fm2 for patients ≥18 years of age or BMI ≥95th Percentile for age and sex for patients \\\u003C18 years of age based on the US CDC criteria.\n* Able to meet contraception requirements.\n\nKey Exclusion Criteria:\n\nParts A and B\n\n* Any clinically significant abnormalities on screening laboratories or physical examination as determined by the Investigator.\n* Active or history of any significant medical condition such as and including renal, hepatic, pulmonary, gastrointestinal, cardiovascular, genitourinary, endocrine, immunologic, metabolic, neurologic or hematological disease.\n* Obesity due to genetic, syndromic, or endocrine etiologies.\n* History of renal transplant, end stage renal disease.\n* Diagnosis of severe psychiatric disorders.\n* Current, clinically significant pulmonary, cardiac, metabolic, or oncologic disease considered severe enough to interfere with the trial and\u002For confound the results.\n* Cigarette smoking or dependence on caffeine, alcohol or drugs; unable or unwilling to abstain completely from caffeine, alcohol and related substances for 24 hours prior to and after study visits.\n* History of recent surgery (within 60 days of Screening).\n* Participation in any clinical trial with an investigational drug\u002Fdevice within 3 months or 5 half-lives, whichever is longer, prior to the first trial dose.\n* Pregnant and\u002For breastfeeding or desiring to become pregnant during this trial.\n\nPart C\n\n* Diagnosis of Prader-Willi syndrome (PWS) or Rapid-onset obesity with hypoventilation, hypothalamic, autonomic dysregulation, neuroendocrine tumor syndrome (ROHHADNET).\n* Weight loss \\>2% in the previous 3 months for patients aged ≥18 years or \\>2% reduction in BMI for patients aged 12 to \\\u003C18 years and\u002For anti-obesity medications for the treatment of obesity.\n* Bariatric surgery or procedure within the last 2 years.\n* Diagnosis of severe psychiatric disorders; any suicidal ideation, attempt or behavior.\n* Current, clinically significant pulmonary, cardiac, metabolic, or oncologic disease considered severe enough to interfere with the trial and\u002For confound the results.\n* History of renal transplant, end stage renal disease.\n* Participation in any clinical trial with an investigational drug\u002Fdevice within 3 months or 5 half-lives, whichever is longer, prior to the first trial dose, or previous participation in a trial with setmelanotide.\n* Pregnant and\u002For breastfeeding or desiring to become pregnant during this trial.\n* Obesity attributable to other genetic or syndromic conditions (eg, PPL \\[pro-opiomelanocortin (POMC), proprotein convertase subtilisin\u002Fkexin type 1 (PCSK1), leptin receptor (LEPR), collectively\\], Bardet-Biedl syndrome \\[BBS\\]) prior to the hypothalamic injury.\n\nPart D\n\n* Weight loss \\>2% in the previous 3 months for patients aged ≥18 years or \\>2% reduction in BMI for patients aged 12 to \\\u003C18 years or therapies for the treatment of obesity or hyperphagia.\n* Metabolic and bariatric surgery (MBS) or procedure within last 6 months.\n* Diagnosis of severe psychiatric disorders; any suicidal ideation, attempt or behavior.\n* Current, clinically significant pulmonary, cardiac, metabolic, or oncologic disease considered severe enough to interfere with the trial and\u002For confound the results.\n* Pregnant and\u002For breastfeeding or desiring to become pregnant during this trial.\n\nOther protocol defined Inclusion\u002FExclusion criteria may apply.",true,"12 Years","65 Years",{"count":58,"type":20},150,[60,61],"PHASE1","PHASE2","The purpose of this study is to evaluate the safety, tolerability, and PK of RM-718 in healthy subjects with obesity and in patients with MC4R Pathway Impairment",[26,64,65],"Prader-Willi Syndrome","PWS",[67,68,69],"melanocortin 4 receptor (MC4R)","MC4R agonism","obesity","2025-12-18",{"date":72,"type":38},"2025-12-22",{"date":74,"type":38},"2024-03-05",{"date":76,"type":20},"2028-11-01",{"name":44,"class":45},7,""]